Melanoma is a skin neoplasm that originates from malignant transformation of melanocytes.
It commonly occurs in the extremities of women and on trunk or head and neck in men.
Metastases are via lymphatic and hematogenous routes.
A 10 mg/kg dose of ipilimumab led to significant improvement in overall survival (OS) in individuals with advanced melanoma compared with a 3 mg/kg dose, but was also associated with a higher number of treatment-related adverse events (TRAEs), according to findings of a recent study.
Individuals with untreated advanced melanoma given a combination of nivolumab and ipilimumab demonstrated greater overall survival (OS) than those on ipilimumab only, according to findings of the CheckMate 067* trial presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, US.
Pembrolizumab is cost-effective in the first-line treatment of advanced melanoma in Hong Kong compared with ipilimumab and standard chemotherapy, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held recently in Singapore.
Prominent members from the Malaysian Society of Allergy and Immunology (MSAI) and Dermatological Society of Malaysia (PDM) came together to establish a coalition called the Malaysian Urticaria Expert Group (MARTEG).